MS
FOLD

Maven Securities’s Amicus Therapeutics FOLD Stock Holding History

Maven Securities’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16M Buy
1,109,882
+320,600
+41% +$4.6M 0.31% 74
2025
Q4 		$11.2M Buy
+789,282
New +$7.75M 0.25% 98
2021
Q3 		– Sell
-64,422
Closed -$634K – 1127
2021
Q2 		$634K Buy
+64,422
New +$629K 0.03% 572
2021
Q1 		– Sell
-51,704
Closed -$1.2M – 1211
2020
Q4 		$1.2M Buy
+51,704
New +$1.06M 0.12% 210

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Maven Securities's FOLD Position: Q1 2026 in Review

Maven Securities increased its Amicus Therapeutics (FOLD) stake by 41% in Q1 2026, buying an estimated $4.6M and bringing the position to 1,109,882 shares worth $16M. The position accounts for 0.31% of the portfolio, ranked #74.

Maven Securities first reported a position in FOLD in Q4 2020 and has held it in 4 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Maven Securities held 1,109,882 shares of Amicus Therapeutics worth $16M as of Q1 2026.
  • Maven Securities bought 320,600 Amicus Therapeutics shares in Q1 2026, an estimated $4.6M.
  • Amicus Therapeutics made up 0.31% of Maven Securities's portfolio in Q1 2026, its #74 holding.
  • Maven Securities first reported a position in Amicus Therapeutics in Q4 2020 and has held it in 4 quarters since.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Maven Securities's 13F filing for Q1 2026, filed 15 May 2026.